Searched for
OTSUKA HOLDINGS
Nikkei ends at three-week low on profit-taking as second half of fiscal year beginsJapan's Nikkei share average ended at a three-week low on Wednesday in a broad sell-off as investors booked profits from the latest rally a...- Japan's Topix hits record high despite US tariffs on pharmaJapan's Topix index reached a record high on Friday. This happened despite pharmaceutical shares facing pressure. The Nikkei index, however...
- Nikkei index jumps as chip stocks rally ahead of Sino-US talksJapan's Nikkei share average advanced on Monday ahead of trade talks between the U.S. and China in London later in the day, with investors ...
- Lupin launches generic version of kidney disorder treatment drug in USLupin Ltd has launched generic Tolvaptan tablets in the US, after receiving USFDA approval. These tablets, with strengths of 15 mg, 30 mg, ...
- Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 rangeJapan's Nikkei share average closed at a fresh 34-year high on Tuesday as trading resumed after a long holiday weekend, with tech-related s...
- Japan's Nikkei hits 7-week high after third consecutive day of gains"Tokyo Electron and others seem to have been affected [by Alphabet and Microsoft]," said Toyo's Otsuka. "If hypergrowth stocks are still ad...
- Japan shares ride earnings to end higher, Delta worries lingerThe Nikkei share average ended the day 0.24% higher at 27,888.15, after earlier marking a mid-July peak of 28,128.61.
- Nikkei slips on global virus woes, caution ahead of US electionsAll but six of the 33 sector sub-indexes on the Tokyo exchange traded lower, with miners, iron and steel and insurers leading declines.
- Hold Hexaware Technologies, target Rs 360: Edelweiss SecuritiesHexaware Technologies is a midcap company, operating in information technology sector.
- Nikkei edges up but gains limited ahead of US-China meetingThe Nikkei share average rose 0.4 per cent to 22,351.06.
- Carlyle in talks to invest $100 million in BDR PharmaBDR clocked Rs 550-600 crore in revenue and around Rs 120 crore in FY18 EBITDA.
- Japan stocks gain in thin trade as markets await US-N.Korea summitThe Nikkei share average rose 0.5 per cent to 22,804.04.
- Health Ministry dragged to court over curbs on TB drugsThe drugs –– Bedaquiline by US drugmaker J&J and Delamanid by Japanese drugmaker Otsuka Pharma –– are the only treatment option for patient...
- Top PE firms join race for Claris Lifesciences’ US businessThe business is expected to be valued at over $500 million and may also attract interest from a Chinese drugmaker and some Indian pharma co...
- Claris to buy-back 14.49 per cent stake for Rs 231.25 crore"The objective of the buy-back is to return surplus cash to the equity shareholders of the company," Claris said in a filing to the BSE.
- Claris transfers two businesses to Japan JV for Rs 1,050 crClaris will continue to hold a 20 per cent stake in the JV, while Otsuka and Mitsui will hold 60 and 20 per cent in it, respectively, a com...
- Claris Lifesciences gets FIPB nod for Japanese JV, Q1 net down by 29%Ahmedabad-based Claris Lifesciences registered de-growth of 29% in its first quarter ended on 31st March 2013.
- Govt approves 12 FDI proposals worth over Rs 2,609 crThe government today said it has approved 12 FDI proposals, including that of pharma firm Claris Otsuka, totalling over Rs 2,609 crore.
- Non-life space gets new playerThe country’s booming non-life insurance segment witnessed the entry of a new player on Wednesday, with Universal Sompo General Insurance C...
- Allahabad Bank insurance deal with Sompo on trackUncertainty over Sompo Japan Insurance’s participation in the Allahabad Bank-led general insurance consortium is now history.
Load More
